Mark C. McKenna - 17 Aug 2023 Form 4 Insider Report for Apogee Therapeutics, Inc. (APGE)

Role
Director
Signature
/s/ Matthew Batters, as attorney-in-fact for Mark McKenna
Issuer symbol
APGE
Transactions as of
17 Aug 2023
Net transactions value
$0
Form type
4
Filing time
21 Aug 2023, 16:06:29 UTC
Previous filing
16 Jun 2023
Next filing
05 Feb 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APGE Stock Option (Right to Buy) Award $0 +50,000 $0.000000 50,000 17 Aug 2023 Common Stock 50,000 $23.60 Direct F1
transaction APGE Stock Option (Right to Buy) Award $0 +100,000 +200% $0.000000 150,000 17 Aug 2023 Common Stock 100,000 $23.60 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents the right to purchase 50,000 shares of the Issuer's common stock, which will vest in thirty-six equal monthly installments over a three-year period from the date of grant, subject to the Reporting Person's continued service to the Issuer.
F2 This option represents the right to purchase 100,000 shares of the Issuer's common stock, which will vest in thirty-six equal monthly installments over a three-year period from the date of grant, contingent upon approval of the option at the Issuer's 2024 Annual Meeting of Stockholders and subject to the Reporting Person's continued service to the Issuer.